
Corcept Therapeutics (CORT) Stock Forecast & Price Target
Corcept Therapeutics (CORT) Analyst Ratings
Bulls say
Corcept Therapeutics is expected to have a positive outlook due to its recent resubmission announcement and potential second approval for relacorilant by YE 2026, with projected sales for its current medication, Korlym, expected to start in 2Q26 and grow to $1.6B in 2034. The company has also reported strong financial results and a successful pharmacy transition, and its recent launch of Lifyorli has shown positive early launch signals, which could lead to increased revenue guidance and a potential multi-product franchise in oncology and ALS. However, risks to this positive outlook include potential delays or challenges in commercialization, clinical and regulatory issues, and competition within the industry.
Bears say
Corcept Therapeutics is expected to perform well in the long term, as evidenced by a Buy rating and a 12-month price target of $95 from an NPV analysis, EV/sales analysis, and EV/earnings analysis. However, there are several risks that could hinder the company's growth, including commercial, clinical and regulatory, reimbursement, financial, legal, and intellectual property risks. Investors should keep a close eye on these risks when considering an investment in Corcept Therapeutics.
This aggregate rating is based on analysts' research of Corcept Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Corcept Therapeutics (CORT) Analyst Forecast & Price Prediction
Start investing in Corcept Therapeutics (CORT)
Order type
Buy in
Order amount
Est. shares
0 shares